XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2024

Fair Value Measurements

Schedule of financial assets and liabilities measured at fair value on a recurring basis

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):


		Fair Value Measurements as of June 30, 2024 Using:
		Quoted Prices in			Significant Other			Significant
		Active Markets for			Observable			Unobservable
		Identical Assets			Inputs			Inputs
		(Level 1)			(Level 2)			(Level 3)			Total
Assets:
Cash equivalents:
Money market funds		$	128,877		$	—		$	—		$	128,877
Total cash equivalents			128,877			—			—			128,877
Exarafenib milestone asset (Note 4)			—			—			2,922			2,922
Equity securities			696			—			—			696
Total financial assets		$	129,573		$	—		$	2,922		$	132,495
Liabilities:
Exarafenib milestone contingent consideration (Note 4)		$	—		$	—		$	2,922		$	2,922
Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value			—			—			—			—
Total financial liabilities		$	—		$	—		$	2,922		$	2,922


		Fair Value Measurements as of December 31, 2023 Using:
		Quoted Prices in			Significant Other			Significant
		Active Markets for			Observable			Unobservable
		Identical Assets			Inputs			Inputs
		(Level 1)			(Level 2)			(Level 3)			Total
Assets:
Cash equivalents:
Money market funds		$	28,352		$	—		$	—		$	28,352
Total cash equivalents			28,352			—			—			28,352
Equity securities			161			—			—			161
Total financial assets		$	28,513		$	—		$	—		$	28,513
Liabilities:
Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value		$	—		$	—		$	1,000		$	1,000